Histone modifications as markers of cancer prognosis: a cellular view

被引：120

作者：

Kurdistani, S. K. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA

来源：

BRITISH JOURNAL OF CANCER | 2007年 / 97卷 / 01期

关键词：

epigenetics; histone modifications; prognosis; biomarker;

D O I：

10.1038/sj.bjc.6603844

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Alterations in modifications of histones have been linked to deregulated expression of many genes with important roles in cancer development and progression. The effects of these alterations have so far been interpreted from a promoter-specific viewpoint, focussing on gene-gene differences in patterns of histone modifications. However, recent findings suggest that cancer tissues also display cell-cell differences in total amount of specific histone modifications. This novel cellular epigenetic heterogeneity is related to clinical outcome of cancer patients and may serve as a valuable marker of prognosis.

引用

页码：1 / 5

页数：5

共 38 条

[1] Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma [J].

Alaminos, M ;

Davalos, V ;

Cheung, NKV ;

Gerald, WL ;

Esteller, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (16) :1208-1219

[2] Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].

Baylin, SB ;

Ohm, JE .

NATURE REVIEWS CANCER, 2006, 6 (02) :107-116

[3] Retinoblastoma protein recruits histone deacetylase to repress transcription [J].

Brehm, A ;

Miska, EA ;

McCance, DJ ;

Reid, JL ;

Bannister, AJ ;

Kouzarides, T .

NATURE, 1998, 391 (6667) :597-601

[4] Akt-mediated phsophorylationof EZH2 suppresses methylation of lysine 27 in histone H3 [J].

Cha, TL ;

Zhou, BHP ;

Xia, WY ;

Wu, YD ;

Yang, CC ;

Chen, CT ;

Ping, B ;

Otte, AP ;

Hung, MC .

SCIENCE, 2005, 310 (5746) :306-310

[5] Epigenetics provides a new generation of oncogenes and tumour-suppressor genes [J].

Esteller, M .

BRITISH JOURNAL OF CANCER, 2006, 94 (02) :179-183

[6] Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].

Esteller, M ;

Garcia-Foncillas, J ;

Andion, E ;

Goodman, SN ;

Hidalgo, OF ;

Vanaclocha, V ;

Baylin, SB ;

Herman, JG .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354

[7] The epigenetic progenitor origin of human cancer [J].

Feinberg, AP ;

Ohlsson, R ;

Henikoff, S .

NATURE REVIEWS GENETICS, 2006, 7 (01) :21-33

[8] Timeline - The history of cancer epigenetics [J].

Feinberg, AP ;

Tycko, B .

NATURE REVIEWS CANCER, 2004, 4 (02) :143-153

[9] Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer [J].

Fraga, MF ;

Ballestar, E ;

Villar-Garea, A ;

Boix-Chornet, M ;

Espada, J ;

Schotta, G ;

Bonaldi, T ;

Haydon, C ;

Ropero, S ;

Petrie, K ;

Iyer, NG ;

Pérez-Rosado, A ;

Calvo, E ;

Lopez, JA ;

Cano, A ;

Calasanz, MJ ;

Colomer, D ;

Piris, MA ;

Ahn, N ;

Imhof, A ;

Caldas, C ;

Jenuwein, T ;

Esteller, M .

NATURE GENETICS, 2005, 37 (04) :391-400

[10] Mutations truncating the EP300 acetylase in human cancers [J].

Gayther, SA ;

Batley, SJ ;

Linger, L ;

Bannister, A ;

Thorpe, K ;

Chin, SF ;

Daigo, Y ;

Russell, P ;

Wilson, A ;

Sowter, HM ;

Delhanty, JDA ;

Ponder, BAJ ;

Kouzarides, T ;

Caldas, C .

NATURE GENETICS, 2000, 24 (03) :300-303

← 1 2 3 4 →